SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " biotech " 225 found 🔀 AI-powered Shuffle
Xtalks Announces its Life Science Webinar Calendar for February 2026
Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!
Designing the future of metabolic health through tissue-selective drug delivery
Founded by MIT alumni, the biotech firm Gensaic develops protein carriers that can deliver therapeutic molecules to specific tissues and cells.
Sepsis-finding biotech Prenosis lands $40M in financing, federal contract
Chicago-based sepsis diagnosing biotech Prenosis announced two $20 million milestones this morning, Series A financing and a large government contract.
Exclusive: VC firm Rock Health considering biotech investments
The San Francisco firm has invested almost exclusively in digital health for 15 years.
Abbott shares sag as global diagnostic, nutrition business sales declines drag on earnings
Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22 as the market digested weaknesses from its fourth-quarter and full-year earnings report.
Mapping the science–technology translational landscape in biomedicine
Nature Biotechnology - A systematic, prospective analysis of the interplay between science and technology in biomedicine can illuminate the pathway for translating scientific insights into tangible...
BeOne CEO on Business Strategy, Biotech Outlook
John Oyler, Co-founder, Chairman and CEO at BeOne Medicines, discusses the company's business strategy and the outlook for the biotech sector. He speaks with Avril Hong and Paul Allen from the sidelines of the JPMorgan Healthcare Conference in San Francisco. (Source: Bloomberg)
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
Exceeded 10,000 patients treated to date with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy manufacturing facility in the U.S.Profitability expected in 2026, driven by continued CARVYKTI® revenue growth and operating margin expansion Treated first patient with in vivo pipeline candidate in investigator-initiated trial Preclinical data from primates provided early validat
Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise
Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced a strategic partnership with McKinney Regulatory Science Advisors ("McKinney"), a premier FDA regulatory consulting firm specializing in nicotine and reduced-risk consumer products, to spearhead its regulatory submission strategy and solidify its commitment to scientific leadership in the oral pouch technology space.
‘An undoing of the scientific method’: Flagship CEO warns of government threats to US biotech industry
The Trump administration spent 2025 taking a sledgehammer to science, obliteratin | The Trump administration spent 2025 taking a sledgehammer to science, obliterating funding and reshaping agencies like the FDA and National Institutes of Health through layoffs and restrictive new policies. In a new letter, Noubar Afeyan, Ph.D., co-founder of Moderna and CEO of Flagship Pioneering, warns that these actions risk undermining the foundations of science itself to the ultimate detriment of health and biotech innovation in America.
Investor behind Moderna says U.S. policy is ‘taking a sledgehammer to our miracle machine’
Noubar Afeyan, one of biotech’s top investors, says U.S. policy is "taking a sledgehammer to our miracle machine."
Obesity, M&A, Biotech Resurgence: A 2026 Guide to Health Stocks
The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth and healthy dividend yields among the industry’s stalwarts. That narrative is changing.
New Era of Fermentation: SINOFN Health’s Global Health Vision
TIANJIN, TIANJIN, CHINA, January 5, 2026 /EINPresswire.com/ — In the wellness-driven era of 2025, the global beverage industry is witnessing a seismic shift from sugary sodas to functional, “alive” alternatives. As gut health becomes the cornerstone of modern vitality, one name has emerged at the intersection of biotechnology and consumer wellness: SINOFN Health Co., Ltd. […]
Editors Pick: Sense, Nonsense and Science Columns
Seed World Europe features the columns of Dr. Joe Schwarcz, Director of McGill University’s Office for Science and Society, for readers who appreciate science with clarity, curiosity, and wit. Known for demystifying chemistry and challenging misinformation, Joe brings an engaging, no-nonsense voice to topics spanning food, biotechnology, health claims, and the science behind everyday phenomena. Each column helps readers separate evidence from hype while exploring how science shapes our world—and the seed sector.
'Stop and re-check everything': Scientists discover 26 new bacterial species in NASA's cleanrooms
Scientists discover 26 new bacterial species in NASA cleanrooms, revealing surprisingly resilient microbes with potential uses in biotechnology and medicine.
Biotech, cannabis, housing, ag all made business headlines in 2025
In The Star's annual year in review, the county's biggest business stories included housing proposals and the aftermath of a major immigration raid.
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
PALO ALTO, Calif., December 11, 2025--Evommune, Inc. (NYSE: EVMN) (the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
Moderna Founder Warns US Doubts on Science Threaten Biotech Edge
The US risks falling behind in biotechnology as the government cuts funding and skepticism over vaccines grows, according to Moderna Inc.’s co-founder and Chairman Noubar Afeyan.
Chinese scientists develop promising stem cell therapy for Parkinson’s
New biotech allows ‘seeds’ planted in the brain to differentiate into new nerve cells, reshaping its neural network.
Conejo Valley’s life science moment has arrived
The Conejo Valley’s life science moment is here — driven by global leaders, emerging innovators, modern infrastructure, and a skilled workforce.
City of Hope, Hoag and UCI Health chose to build in Irvine, what makes the area attractive for health-care investment?
The billions of dollars in investments coming online more than double the number of hospital beds in the city, add thousands of jobs and makes Irvine a “biomedical, biotechnical” center…
Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health
Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a significant step in Yuyu Pharma's plan to become a more active global player in the fast-growing animal health sector.
Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer
MUTTENZ, Switzerland, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company pioneering innovation in peritoneal dialysis (PD), is pleased to announce the appointment of Andreas Schuh as Chief Financial Officer (CFO), effective December 1, 2025. Andreas Schuh joins Opterion with over 20 years of leadership experience across biotech, pharma, and medical devices. He has held senior finance and operations roles at Nuclidium, Jeito, Roivant, Novartis, and Al
Trump administration science assault slams major Bay Area economic engine, threatens ‘amazing innovations’
Investors and young scientists are pulling back from biotech, amid broader attacks on science under Trump, industry representatives said.
Trump administration science assault slams major Bay Area economic engine, threatens ‘amazing innovations’
Investors and young scientists are pulling back from biotech, amid broader attacks on science under Trump, industry representatives said.